Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Solrikitug in adults with eosinophilic esophagitis
NL-OMON59074Phase 2Completed
- Sponsor
- NI-One
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of solrikitug in eosinophilic esophagitis (EoE) (3 arms), sponsored by NI-One. Primary endpoints: Histologic response, Dysphagia symptom improvement and 3 more. Started Jul 2025; status: completed.
02
Drugs
solrikitug
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on NL-OMON59074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59074.